Compare Johnson & Johnson (JNJ) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Omnicom Group Inc. — how do they compare? Johnson & Johnson trades at $260.45 (market cap $618.09B), while Omnicom Group Inc. trades at $76.68 (market cap $20.97B). The key difference: Johnson & Johnson is far larger — about 29.5× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (4.19%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Omnicom Group Inc. for 63 Days on average.
| JNJ | OMC | |
|---|---|---|
Market Cap | $618.09B | $20.97B |
Volume | 6,050,983 | 2,092,899 |
Sector | Health | Media |
52-Week High | $278.43 | $88.94 |
52-Week Low | $186.00 | $67.27 |
Typical Hold Time | 129 Days | 63 Days |
Enterprise Value | $646.37B | $29.05B |
Dividend Yield | 2.09% | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Omnicom Group (OMC) trades at $76.32, up 1.94% on the day, with a bullish technical signal but mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, with a high P/E ratio of 206.62 but attractive P/S of 0.86. Recent news highlights leadership in digital marketing and $3.3 billion in new H1 2026 billings, supporting positive sentiment.
Outlook is cautiously optimistic given analyst consensus price target of $100.50 (32% upside) and strong institutional interest, but risks include ad market volatility, high debt, and thin net margins. The stock offers value through a 4.2% dividend yield and post-merger synergies, though investors should monitor earnings consistency and macroeconomic pressures on advertising spend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
